Emily Binning
Research Subjects
Research Interests
Emily Binning has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Adam Thomas Crawford Booth
Huma Therapeutics Limited London United Kingdom
1 shared publication - Alain Bernard Labrique
Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
1 shared publication - Aleksa Despotovic
Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
1 shared publication - Angus Bruno Reed
Huma Therapeutics, London, United Kingdom
1 shared publication - Arrash Yassaee
School of Public Health, Imperial College London, London, United Kingdom
1 shared publication - Benjamin Klasmer
Huma Therapeutics Limited
1 shared publication
Latest Publications
- Open Access
Machine learning approach to dynamic risk modeling of mortality in COVID-19: a UK Biobank study
The COVID-19 pandemic has created an urgent need for robust, scalable monitoring tools supporting stratification of high-risk patients. This research aims to develop and validate prediction models, using the UK Biobank, to estimate COVID-19 mortality risk in confirmed cases. From the 11,245 participants testing positive for COVID-19, we develop a data-driven random forest classification model with excellent performance (AUC: 0.91), using baseline characteristics, pre-existing conditions, symptoms, and vital signs, such that the score could dynamically assess mortality risk with disease deterioration. We also identify several significant novel predictors of COVID-19 mortality with equivalent or greater predictive value than established high-risk comorbidities, such as detailed anthropometrics and prior acute kidney failure, urinary tract infection, and pneumonias. The model design and feature selection enables utility in outpatient settings. Possible applications include supporting individual-level risk profiling and monitoring disease progression across patients with COVID-19 at-scale, especially in hospital-at-home settings.
Open AccessMachine learning approach to dynamic risk modeling of mortality in COVID-19: a UK Biobank study
The COVID-19 pandemic has created an urgent need for robust, scalable monitoring tools supporting stratification of high-risk patients. This research aims to develop and validate prediction models, using the UK Biobank, to estimate COVID-19 mortality risk in confirmed cases. From the 11,245 participants testing positive for COVID-19, we develop a data-driven random forest classification model with excellent performance (AUC: 0.91), using baseline characteristics, pre-existing conditions, symptoms, and vital signs, such that the score could dynamically assess mortality risk with disease deterioration. We also identify several significant novel predictors of COVID-19 mortality with equivalent or greater predictive value than established high-risk comorbidities, such as detailed anthropometrics and prior acute kidney failure, urinary tract infection, and pneumonias. The model design and feature selection enables utility in outpatient settings. Possible applications include supporting individual-level risk profiling and monitoring disease progression across patients with COVID-19 at-scale, especially in hospital-at-home settings.